Doctors don’t prescribe peptides — because they were never taught.

The three barriers, in order

When a reader asks why their primary-care physician won’t engage on the peptide question, there are three plausible answers, all of them partially true. There’s no CPT code for the appointment — meaning no clean billing path, no reimbursement, no time in a fifteen-minute slot to discuss a compound the physician doesn’t get paid to discuss. There’s liability exposure — prescribing an off-label compound the malpractice insurer doesn’t recognize is a career risk with no career upside. And there’s the training problem — medical school didn’t cover peptides, residency didn’t cover them, and nothing in the post-licensure continuing-medical- education stream has filled the gap.

All three are real. Two of them are downstream. The training gap is the source. Get the training right and the billing and liability problems become solvable engineering problems instead of structural ones. Leave the training gap in place and the other two barriers are unreachable, because the physician can’t advocate for a billing code or insurer coverage on a topic they don’t feel competent in.

The training gap is the load-bearing wall

The average US medical-school curriculum covers pharmacology in a specific way. The lectures are organized around drug classes that map onto the diseases the institution is set up to treat — antibiotics, antihypertensives, statins, SSRIs, oncology agents, the rest of the standard formulary. Peptide therapeutics outside of the few that became major pharma franchises (insulin, GLP-1 agonists, leuprolide) don’t get a chapter. They don’t get a lecture. They don’t appear on the boards.

Residency reinforces what the boards rewarded. A new primary-care physician finishes their training with deep knowledge of the conditions and compounds the curriculum prioritized, and a structural blank space where the peptide category should be. That blank space isn’t skepticism. It’s absence. When a patient walks in and asks about BPC-157, the physician’s honest answer is closer to “I have no working knowledge of this” than to “the evidence doesn’t support it.” The dismissal that follows is protective — for the physician’s time, the appointment’s scope, and the boundaries of what they were trained to be responsible for.

Who funds CME — and what that buys

Continuing medical education is supposed to be the mechanism that updates physicians on what the curriculum missed. In practice, a large share of CME activity in the United States is funded directly or indirectly by commercial interests, primarily pharmaceutical manufacturers and medical-device companies, through what the accreditation system labels “commercial support.”¹ The ACCME reports the totals each year. They have run, for more than a decade, in the hundreds of millions to low billions of dollars in commercial support across accredited US CME providers.

That funding model has a predictable consequence. The topics that get developed, presented, and credited as CME tend to be topics that map onto a commercially viable product line. A novel monoclonal antibody with a twenty-year patent runway and a billion-dollar trial program gets a comprehensive CME curriculum the year it launches. A short peptide that any compounding pharmacy can prepare and that nobody owns the exclusive rights to gets nothing. The peer-reviewed literature on industry-funded CME and on industry sponsorship of clinical research has been documenting this pattern for twenty years.²³ It’s not a conspiracy. It’s the natural output of who pays for what.

The result, for the peptide question, is that the system designed to teach physicians what their original education missed reproduces the same blind spot. You can’t fund a CME chapter on a compound nobody is selling at scale. You can’t fund it through the compounding pharmacies, which don’t have the margin structure to bankroll national curriculum development. You can’t fund it through patient groups, which don’t move money the way industry does. The chapter doesn’t exist because the chapter doesn’t have a sponsor.

The CPT code — downstream of training

The Current Procedural Terminology (CPT) coding system determines what a physician can bill for during a clinical visit. There’s no CPT code for “a thirty-minute consultation on whether the patient is a candidate for a tissue-repair peptide protocol.” The closest billable codes are time-based evaluation-and- management visits, which a physician can technically use, but the documentation burden, the prior-authorization risk if a payer audits the chart, and the absence of a clean clinical guideline to anchor the assessment all push the conversation off the schedule.

That sounds like the real barrier, until you ask the adjacent question: why isn’t there a CPT code? Codes get added when a constituency of physicians lobbies the AMA’s CPT Editorial Panel to add them. That constituency doesn’t exist for peptide consults because the trained physicians don’t exist in the numbers it would take. The billing barrier is downstream of the training barrier. Train the physicians and the billing infrastructure follows, the same way it followed for GLP-1 prescribing once those compounds penetrated primary care.

Liability — also downstream

Malpractice underwriting rewards conformity. A physician who prescribes within the standard of care and within the formulary their professional society endorses gets a predictable premium. A physician who prescribes off-label compounds their society hasn’t issued guidance on starts answering uncomfortable questions at renewal time. The category-level absence of guidance creates the underwriting exposure.

Guidance is written by the professional societies. The societies write it when there’s a critical mass of trained members asking for it. Same training problem. The liability barrier dissolves once the curriculum catches up and the guidelines arrive. Until that happens, the rational physician avoids the category.

Who fills the vacuum

Functional-medicine clinics, longevity practices, and integrative-medicine MDs fill the vacuum. They’ve sought out the training the standard curriculum didn’t provide, often through specialty fellowships or self-directed clinical study. They charge cash because the insurance billing pathway doesn’t exist for them either, which conveniently sidesteps the CPT and prior-authorization problem. They’ve made their peace with the underwriting questions. And they get called quackery for it by colleagues who, by their own admission, weren’t taught the category and don’t feel competent to evaluate it.

That dynamic is the part most peptide-skeptical commentary misses. The mainstream-versus-functional framing reads like an evidence dispute. It isn’t. It’s a labor-supply dispute. Mainstream medicine didn’t produce a workforce equipped to handle the peptide conversation, the functional-medicine sector backfilled the demand, and the resulting boundary fight looks like a fight over science when it’s actually a fight over who gets to own the territory.

The frame I’d carry forward

Two takeaways for a reader trying to make sense of why their physician won’t engage on peptides.

First, the dismissal isn’t usually an evidence judgment. It’s a scope-of-competence judgment, and a fair one given the training the physician received. Don’t hold it against them. Hold it against the curriculum, the CME funding model, and the boards that decided which compounds deserved a chapter.

Second, the right move when you hit that wall is to find a physician whose training fills the gap. They exist now in greater numbers than at any point in the last decade, particularly since the February 2026 HHS reclassification made the prescription route legal again for fourteen of the previously restricted compounds. Functional-medicine MDs, longevity clinics, integrative-medicine practices. Bring your bloodwork. Bring your history. Bring your questions. The conversation you couldn’t have in a fifteen-minute primary-care slot is the conversation those clinicians built their practices around.

The financial structure of US medicine, not the evidence on peptides, is what built the standoff. The evidence is what it is, and it varies by compound. The structure is what kept your physician from being able to talk you through it.

References

1. Accreditation Council for Continuing Medical Education. ACCME Annual Report Data. accme.org.
2. Steinbrook R. Industry funding of continuing medical education. JAMA. 2008. PubMed.
3. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003;326(7400):1167-70. PubMed.
4. American Medical Association. What doctors want patients to know about injectable peptides. AMA public health. ama-assn.org.
5. BioPharma Dive. FDA moves toward easing restrictions on certain peptides. 2026. biopharmadive.com.